Back
Science

UK Government Announces £1.5 Billion Investment in Life Sciences R&D, Sets Ambitious Sector Growth Targets

Generated on: Last updated: 1 sources
View source

UK Life Sciences: A National Asset Driving Growth and Innovation

The UK Science and Tech Secretary recently delivered a speech highlighting the vital role of the British life sciences and biotech sector in the nation's economic growth and healthcare advancements.

Sector Contribution and Ambitions

The sector currently employs over 350,000 people and contributes more than £145 billion to the UK economy. Recent significant breakthroughs underscore its impact, including Autolus's leukaemia treatment, Vertex's gene-editing therapy for blood disorders, and Bristol Myers Squibb's rapid immunotherapy for cancer patients.

The government's stated goal is for the UK to become the top life sciences economy in Europe by 2030 and third globally by 2035.

This ambition is shared across government leadership, including the Chancellor and Prime Minister, signalling a united strategic focus.

Government Initiatives and Investment

Since the launch of the Life Sciences Sector Plan six months prior, progress has been reported in several key areas:

  • Improving the NHS as a customer for innovation.
  • Accelerating clinical trials.
  • Establishing a new Health Data Research Service (HDRS) for secure access to national health data.
  • Securing a landmark pharmaceutical deal with the United States.
  • Committing the largest ever government investment into R&D funding, exceeding £38 billion for UKRI.

Specific financial commitments include a guaranteed £1.5 billion for R&D in the life sciences sector over the next four years. Additionally, the MRC Lab for Molecular Biology in Cambridge is set to receive 10 years of guaranteed funding, starting with approximately £50 million annually over the next four years within the current Spending Review period.

Unlocking Private Investment

The government also emphasized the crucial importance of unlocking private investment to complement public funds. Initiatives mentioned to achieve this include:

  • The Mansion House Accord.
  • The Pension Schemes Bill, aimed at driving consolidation in the pensions market to boost investment in UK companies.
  • The British Business Bank's (BBB) £4 billion Industrial Strategy Growth Capital initiative, launched in June, designed to help promising firms scale up and retain them in the UK.

Conclusion

The Secretary concluded by stating that the life sciences sector is a significant national asset.

Through a collaborative government and business partnership, the overarching objectives are to provide patients with faster access to improved drugs, enable companies to scale and remain in the UK, create jobs, and stimulate the economy.